Valuation: Applied Therapeutics, Inc.

Market Cap 15.25M 13.37M 12.35M 11.41M 21.62M 1.46B 22.06M 148M 57.67M 714M 57.25M 56M 2.48B P/E 2023
-2.36x
P/E 2024 -1.13x
Enterprise Value -61.36M -53.82M -49.68M -45.91M -87.02M -5.88B -88.77M -597M -232M -2.88B -230M -225M -9.98B EV / Sales 2023
20,974,366x
EV / Sales 2024 50,596,512x
Free-Float
95.24%
Yield 2023 *
-
Yield 2024 -
1 day+0.19%
6 months+2.79%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
22.27
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 03/02/2026
Corporate Secretary - 03/02/2026
Corporate Officer/Principal - 21/01/2025
Director TitleAgeSince
Director/Board Member - 03/02/2026
Date Insider Type Main position Quantity % Market Cap.
03/02Issuer sale

Director

328,690 0.2278%
03/02Issuer sale

Director

328,690 0.2278%
03/02Issuer sale

Director

393,053 0.2724%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%-72.09%-92.43% 15.7M
-1.28%-4.36%+69.72%+124.46% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.70%+3.12%+42.78%-2.68% 18.69B
-0.53%+0.48%+37.29%-26.30% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-1.34%+1.15%+35.22% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +0.14%+3.61%+43.48%+125.78% 23.94B
Weighted average by Cap. -0.33%+2.20%+57.31%+143.19%

Financials

2023 2024
Net sales 9.99 8.76 8.09 7.48 14.17 956.85 14.46 97.28 37.8 468.25 37.53 36.7 1.63K 0.46 0.4 0.37 0.34 0.65 43.57 0.66 4.43 1.72 21.32 1.71 1.67 74.01
Net income -120M -105M -96.98M -89.62M -170M -11.47B -173M -1.17B -453M -5.61B -450M -440M -19.48B -106M -92.64M -85.53M -79.04M -150M -10.11B -153M -1.03B -400M -4.95B -397M -388M -17.18B
Net Debt -49.12M -43.08M -39.78M -36.76M -69.67M -4.7B -71.06M -478M -186M -2.3B -184M -180M -7.99B -76.6M -67.19M -62.03M -57.32M -109M -7.33B -111M -746M -290M -3.59B -288M -281M -12.46B
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. APLT Stock